li001

Researchers found that adding the targeted drug niraparib to standard treatment (abiraterone acetate and prednisone) significantly slows the progression of advanced prostate cancer in men with specific DNA repair gene mutations. The trial included 696 men whose cancer had spread and who carried Homologous Recombination Repair (HRR) gene mutations, such as BRCA1 or BRCA2. The combination therapy reduced […]

Izalontamab brengitecan (iza-bren; BL-B01D1), a first-in-class bispecific antibody-drug conjugate, showed significantly better and more durable outcomes than chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC) who had already undergone multiple treatments. In the Phase 3 BL-B01D1-301 trial involving 386 patients who had received at least two prior therapies, including platinum-based chemotherapy and a

A major international clinical trial showed that adding the drug enzalutamide to standard hormone therapy can cut the risk of death by over 40% in men whose prostate cancer returns after initial surgery or radiation. This combination therapy was tested on over 1,000 men with high-risk recurrent prostate cancer—meaning their PSA levels (a marker for the disease) were rising

Researchers have found that triple-negative breast cancer (TNBC) depends heavily on lipids—fatty acids in the body—for its growth, linking obesity to more aggressive tumor development. In preclinical mouse models, excess lipids accelerated tumor growth, while reducing lipid levels slowed it significantly. Lipids appear to act as “building blocks” that fuel rapid cancer cell proliferation. These